Introduction

Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest growth is expected in the non-insulin market, the insulin market will continue to dominate, generating revenues of $224m 10 years from now.

Reasons to Purchase

*Identify key opportunities and threats that will impact the use and uptake of new and existing products

*Quantify the future size and scope of the Australian antidiabetics market and predict the performance of key compounds

*Understand critical success factors in growing and defending antidiabetic brand franchises from new entrants and generics


Report Highlights

[Studien Infos ausblenden]